United Kingdom



Total dual-trancher extends hybrid revival

LONDON, Sept 29 (IFR) - After spending much of 2016 in the doldrums, corporate hybrid issuance is staging a revival on the back of investors' search for yield, with Total announcing on Thursday that it was aiming to raise up to 2.5bn in the format.

12:52pm BST

BRIEF-Actinogen Medical received feedback from FDA

* Will communicate with FDA and if questions cannot be resolved in time, will not be able to recruit patients in phase ii trial by end of 2016

12:40pm BST

BRIEF-GlaxoSmithKline appoints new consumer healthcare CEO

* GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK consumer healthcare

12:40pm BST

BRIEF-Tong Ren Tang enters assets transfer agreement with Bozhou Herbal Pieces

* Tong Ren Tang-connected Transaction Disposal Of The Target Assets

12:37pm BST

Amgen and Arrowhead to develop gene-therapies for heart disease

Sept 29 Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and team up with the company to develop gene-silencing therapies for heart disease.

12:36pm BST
GlaxoSmithKline PLC 1,660.00p +0.33%
AstraZeneca PLC 5,090.00p -0.62%
Shire PLC 5,144.00p +0.70%


  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.